Video: Every Case Tells a Story| Webinar: ACR/CHEST ILD Guidelines in Practice

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

  • Conditions
    • Axial Spondyloarthritis
    • Gout and Crystalline Arthritis
    • Myositis
    • Osteoarthritis and Bone Disorders
    • Pain Syndromes
    • Pediatric Conditions
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
    • Systemic Sclerosis
    • Vasculitis
    • Other Rheumatic Conditions
  • FocusRheum
    • ANCA-Associated Vasculitis
    • Axial Spondyloarthritis
    • Gout
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Systemic Lupus Erythematosus
  • Guidance
    • Clinical Criteria/Guidelines
    • Ethics
    • Legal Updates
    • Legislation & Advocacy
    • Meeting Reports
      • ACR Convergence
      • Other ACR meetings
      • EULAR/Other
    • Research Rheum
  • Drug Updates
    • Analgesics
    • Biologics/DMARDs
  • Practice Support
    • Billing/Coding
    • EMRs
    • Facility
    • Insurance
    • QA/QI
    • Technology
    • Workforce
  • Opinion
    • Patient Perspective
    • Profiles
    • Rheuminations
      • Video
    • Speak Out Rheum
  • Career
    • ACR ExamRheum
    • Awards
    • Career Development
  • ACR
    • ACR Home
    • ACR Convergence
    • ACR Guidelines
    • Journals
      • ACR Open Rheumatology
      • Arthritis & Rheumatology
      • Arthritis Care & Research
    • From the College
    • Events/CME
    • President’s Perspective
  • Search

Shingles Vaccination Not at Goal Levels for U.S. Seniors

Madeline Kennedy  |  November 28, 2016

“The pain of shingles can be debilitating and is not easily treated,” Dr. Barbara Yawn, a professor at the University of Minnesota in Minneapolis, tells Reuters Health by email.

The pain and itching of shingles can be so bad that people may not be able to do their usual activities, says Yawn, who was not involved in the study.

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

“In the oldest group, the disability can be so marked that people are unable to provide their own care and become dehydrated and may end up in the hospital because they cannot even get up to get a drink due to the pain,” Yawn adds.

“Shingles is a preventable disease that can have adverse effects on your quality of life,” Yawn says. “It is better to prevent shingles than try to treat after it has occurred.”

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

“Herpes zoster is a disease that a vaccine may help to prevent, yet the vaccination rate remains low,” Zhang says. “It is imperative that people talk with their physician or pharmacist to determine if they are eligible for vaccination against herpes zoster.”


Reference

  1. Zhang D, Johnson K, Newransky C, et al. Herpes zoster vaccine coverage in older adults in the U.S., 2007–2013. Am J Prev Med. 2016 Oct 26.

Page: 1 2 | Single Page
Share: 

Filed under:Conditions Tagged with:CDCelderlyherpes zostershinglesvaccinationvaccine

Related Articles

    Immunizations in Immunocomprised Patients

    August 1, 2009

    Vaccines can help minimize certain diseases

    The End of the Beginning: COVID-19 Vaccines & Other Conundrums

    December 9, 2020

    “It’s like winning Powerball.” For months, there has been a steady trickle of questions from my patients, asking for my opinion about the new vaccines being developed to prevent COVID-19. More to the point, they want to know if they should be vaccinated. ad goes here:advert-1ADVERTISEMENTSCROLL TO CONTINUEAfter some fits and starts, I finally struck…

    Live Herpes Zoster Vaccine Fails to Provide Long-Term Protection in RA Patients on Tofacitinib

    April 21, 2020

    (Reuters Health)—The live herpes zoster vaccine does not provide reliable long-term protection in rheumatoid arthritis (RA) patients taking tofacitinib, a recent study suggests. Current ACR guidelines conditionally recommend that patients with RA who are 50 years and older be vaccinated against herpes zoster prior to starting therapy with the Janus kinase (JAK) inhibitor tofacitinib or…

    Zoster Reactivation Risk in Patients Treated with Cyclophosphamide

    December 18, 2018

    Varicella-zoster-virus (VZV) reactivation, which can cause patients to develop herpes zoster (i.e., shingles), occurs more frequently in patients with systemic vasculitis and systemic lupus erythematosus (SLE) who have received intravenous cyclophosphamide than in otherwise healthy adults, according to a retrospective study published in The Journal of Rheumatology by researchers in France.1 The study also shows…

  • About Us
  • Meet the Editors
  • Issue Archives
  • Contribute
  • Advertise
  • Contact Us
  • Copyright © 2025 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies. ISSN 1931-3268 (print). ISSN 1931-3209 (online).
  • DEI Statement
  • Privacy Policy
  • Terms of Use
  • Cookie Preferences